Table 2.

CINSARC prospective clinical trials.

Trial number	Phase	Title	Allocation	Intervention model	Primary outcomes	Secondary outcomes
NCT03805022	III	Benefit of intensified peri-operative chemotherapy within High-risk CINSARC patients with resectable soft-tissue sarcomas (CIRSARC)	Randomised	Parallel assignment	- Metastasis progression-free survival [3 years]	- Loco-regional relapse-free survival [3 years] - Progression-free survival [3 years] - Overall survival [3 years] - Best overall response as per RECIST v1.1 [6 months] - Histological response [6 months] - Adverse events/Toxicity as per NCI-CTCAE v5.0 [6 months]
NCT02789384	N/A	Prognostic value of the CINSARC signature and correlation with chemotherapy efficacy in soft-tissue sarcomas. A Biomarker Study. (NEOSarcomics)	N/A	Observational- Single Group Assignment	- Best overall response as per RECIST v1.1 [6 months]	- Histological response [6 months] - Metastasis-free survival [3 years] - Overall survival [3 years] - Adverse events/Toxicity as per NCI-CTCAE v4.0
NCT04307277	III	Interest of peri-operative chemotherapy in patients with CINSARC high-risk localised Grade 1 or 2 soft tissue sarcoma	Randomised	Parallel assignment	- Metastasis-free survival [5 years]	- Disease-free survival [5 years] - Toxicity as per NCI-CTCAE v5.0 - Overall survival [5 years]